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Summary
 
Active Heymann nephritis (HN) is a rat model of human idiopathic membranous nephropathy
in which injury is thought to be mediated by membrane attack complex of complement
(MAC) activated by antibody (Ab) to glomerular epithelial cells. Recent work has shown that
HN develops in C6-deficient rats which cannot assemble MAC, and that infiltration of acti-
vated cytotoxic CD8
 
1
 
 T cells and macrophages into glomeruli coincides with proteinuria. This
study examined the role of CD8
 
1
 
 T cells in mediating glomerular injury in HN by permanent
CD8
 
1
 
 cytotoxic T cell depletion via adult thymectomy (ATx) and anti-CD8 mAb. Groups of
rats were depleted of CD8
 
1
 
 T cells either before immunization for HN or 6 wk after immuni-
zation when Ab responses and glomerular IgG deposition were well established. These were
compared with groups of HN, ATx/HN, and complete Freund’s adjuvant (CFA) controls.
Neither group of CD8
 
1
 
 T cell–depleted rats developed proteinuria, although there was normal
development and deposition of Ab. CD8
 
1
 
 T cell–depleted rats developed neither T cell or
macrophage infiltrates nor their effector cytokines, which are present in glomeruli of rats with
HN. Examination of lymph node (LN) draining sites of immunization showed these findings
were not explained by altered immune events within these LNs. It was concluded that CD8
 
1
 
cytotoxic T cells are essential to the mediation of glomerular injury in HN and may be relevant
to the pathogenesis and treatment of membranous nephropathy.
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I
 
t has been assumed that most forms of glomerulonephri-
tis (GN)
 
1
 
 are mediated by Ab and complement because
they are readily detected in glomeruli. There is increasing
evidence that effector T cells mediate injury in proliferative
forms of GN (1, 2). In membranous nephropathy, one of
the commonest forms of GN in humans, glomerular injury
is thought to be mediated solely by Ab-mediated activation
of the membrane attack complex (MAC) of complement
(3). Active Heymann nephritis (HN) is a rat model of
membranous GN (4) induced in susceptible strains of rats
by immunization with a renal tubular antigen preparation
(Fx1A) in CFA (5) that results in an anti-Fx1A Ab re-
sponse. This Ab forms glomerular subepithelial immune
deposits that activate MAC (6–8). The recent discovery
that C6-deficient PVG rats develop active HN and pro-
teinuria, despite being unable to assemble MAC, casts
doubt on the role of MAC as the mediator of injury in this
model (9). This study examined whether effector T cells
mediate injury to the glomerulus in HN.
Early studies on HN demonstrated classic delayed-type
responses to Fx1A (10), lymphocyte cytotoxicity against re-
nal cells (11, 12), and that sensitized lymphocytes can pas-
sively transfer disease to tolerant hosts (13). An interstitial
mononuclear cell infiltrate of CD4
 
1
 
 and CD8
 
1
 
 T cells has
been described in HN (14, 15), as have glomerular infil-
trates of T cells and macrophages (16–18). CD8
 
1
 
 T cells
infiltrate glomeruli immediately before the onset of pro-
teinuria (18) and temporary depletion of CD8
 
1
 
 T cells by
 
1
 
Abbreviations used in this paper: 
 
ANOVA, analysis of variance; ATx, adult
thymectomy; GEC, glomerular epithelial cells; GN, glomerulonephritis;
HN, Heymann nephritis; iNOS, inducible nitric oxide synthase; IP, im-
munoperoxidase; MAC, membrane attack complex (of complement);
RT-PCR, reverse transcription PCR.
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anti-CD8 mAb therapy from the time of immunization de-
lays the onset of proteinuria (17). In this study, we exam-
ined what role CD8
 
1
 
 T cells may play in the pathogenesis
of HN by permanent depletion using a combination of
anti-CD8 mAb therapy and adult thymectomy (ATx) (19).
CD8
 
1
 
 T cell–depleted rats did not develop proteinuria,
even though they made a normal Ab response to the im-
munizing antigen and deposited IgG in their glomeruli.
This suggests an important effector role for cytotoxic CD8
 
1
 
T cells in HN. This was further supported by the finding of
Th1, cytotoxic T cell, and macrophage cytokine mRNA in
glomeruli from HN but not in CD8
 
1
 
 T cell–depleted
glomeruli. CD8
 
1
 
 T cell depletion did not alter the produc-
tion of serum IgG Ab isotypes, or the induction of Th1
(IFN-
 
g
 
, TNF-
 
b
 
) and Th2 (IL-4) cytokine mRNA in pop-
liteal LN draining sites of immunization when compared
with HN rats. This confirmed there was no alteration of either
Th1 or Th2 CD4
 
1
 
 cell activation in LNs. Taken together,
these findings support a role for the CD8
 
1
 
 effector T cell as
the principal mediator of glomerular injury in HN.
 
Materials and Methods
 
Rats.
 
Inbred male Lewis rats (Lew/ssn) were purchased from
the Animal Resource Centre, Perth, W.A., Australia. Sprague
Dawley rats used to produce Fx1A were acquired from the Ani-
mal Breeding & Holding Unit, University of New South Wales,
Sydney, Australia. Water and standard chow were available ad li-
bitum. All procedures were performed under general anesthesia,
with postoperative buprenorphine analgesia. Animal work was
approved by the Animal Care and Ethics Committee, University
of New South Wales.
 
mAbs.
 
MRC OX-8, a mouse anti–rat IgG1, recognizes
CD8
 
1
 
 T cytotoxic and NK cells (20), and was produced as tissue
culture supernatant from the MRC-OX-8 clone (a gift from Dr.
Alan Williams, Sir William Dunn School of Pathology, Oxford,
UK). Control mAb was A6, a mouse anti–human CD45R0 IgG1
that does not react with rat tissue (21). mAb supernatant had 0.5–1
mg of Ig on assayed immunodiffusion (21) and had 
 
,
 
0.6 U/ml of
endotoxin as assayed by a Limulus amebocyte lysate assay (Coatest
Gel-LAL, Chromogenix, MoIndal, Sweden).
FITC- and PE-conjugated mouse anti–rat mAbs (PharMingen,
San Diego, CA) used for FACS
 
Ò
 
 (Becton Dickinson, San Jose,
CA) analysis included: G4.18, which recognizes CD3
 
1
 
 T cells
(22); MRC OX-35, which recognizes CD4
 
1
 
 T cells and some
macrophages (23); MRC OX-8, which recognizes CD8
 
1
 
 T cy-
totoxic and NK cells (20); and MRC OX-33 (24), which recog-
nizes a form of CD45 found only on B cells. The mAbs used for
immunoperoxidase (IP) staining were: R73 to 
 
a/b
 
-TCR recep-
tors on T cells (25); W3/25, which recognizes CD4
 
1
 
 T cells and
some macrophages (26); MRC OX-8; 3.2.3, which recognizes
NK cells (27); ED-1, which recognizes most macrophages and
some dendritic cells (28); and MRC OX-12, which recognizes 
 
k
 
light chains and was used to identify glomerular IgG deposition
(29). Goat anti–rat C3 Ab was used to identify glomerular C3
deposition on IP.
 
Antigen and Immunization.
 
Fx1A was prepared from outbred
Sprague-Dawley rats as previously described (5, 30). HN (CFA/
Fx1A) and control (CFA alone) groups were immunized as previ-
ously described (18).
 
Experimental Protocol.
 
Groups of five male Lewis rats immu-
nized with Fx1A/CFA were depleted of CD8
 
1
 
 T cells either be-
fore immunization or 6 wk after immunization, and were com-
pared with untreated HN and control groups. All rats were
immunized from the same batch of Fx1A/CFA.
 
CD8
 
1
 
 T Lymphocyte Depletion.
 
CD8
 
1
 
 T cells were perma-
nently depleted by combined ATx and MRC OX-8 as described
(19). ATx was carried out 2 wk before immunization. MRC
OX-8 was administered as 1.0 ml of tissue culture supernatant in-
traperitoneally daily for 10 d, beginning on the day of ATx for
the early CD8
 
1
 
 T cell depletion group and 6 wk after immuniza-
tion for the late CD8
 
1
 
 T cell depletion group.
 
Assessment of Disease Activity.
 
24-h urine protein excretion
was measured by colorimetric assay (Bio-Rad, Hercules, CA).
Anti-Fx1A Ab titers were determined by ELISA as previously de-
scribed (18), using alkaline phosphatase–conjugated Abs: sheep
anti–rat Ig Fab fragments (Boehringer Mannheim, GmbH, Mann-
heim, Germany) and mouse anti–rat IgG1, IgG2a, and IgG2b
(PharMingen, San Diego, CA). Glomerular Ig deposition was
demonstrated by IP of renal cortex using MRC OX-12. Glomer-
ular C3 deposition was demonstrated by IP of renal cortex using
anti-C3 Ab.
 
FACS
 
Ò
 
 Analysis.
 
Lymphocyte subset analysis of PBLs and
LNs was performed by FACS
 
Ò
 
 analysis (FACScan
 
Ò
 
; Becton
Dickinson). Single cell suspensions of lymphocytes were prepared
as previously described (31), and directly stained with FITC- and
PE-conjugated mouse anti–rat mAb to cell surface antigens (see
above). Full blood counts were performed on an automated
counter (Coulter Corp., Miami, FL).
 
Isolation of Intact Glomeruli.
 
Glomeruli for PCR and IP were
isolated by graded sieving to 
 
.
 
95% purity as previously described
(18, 32).
 
IP Cytochemistry.
 
IP staining of renal cortex cross-sections
and isolated glomeruli for all Abs except anti-C3 was performed
as previously described (18), using an indirect peroxidase–antiper-
oxidase technique: step one, mouse anti–rat mAb (described
above); step two, rabbit anti–mouse Ig (Dako, Copenhagen,
Denmark); step three, peroxidase–monoclonal mouse antiperoxi-
dase (Dako). C3 staining of renal cortex cross-sections used a sin-
gle-step technique with goat anti–rat C3 Ab peroxidase immuno-
conjugate (Nordic Immunology, Tilberg, The Netherlands).
 
Semiquantitative Reverse Transcription PCR.
 
Reverse transcrip-
tion (RT)-PCR for mononuclear cell cytokine mRNA in renal
cortex, isolated glomeruli, and popliteal lymph nodes was per-
formed as previously described (18). Semiquantitation of RT-
PCR product involved cycle titration at five-cycle intervals (33).
Primer and probe oligonucleotide sequences for IL-2, IL-4, IL-5,
IL-6, IL-10, granzyme A, IFN-
 
g
 
, perforin/cytolysin, TNF-
 
a
 
,
lymphotoxin/TNF-
 
b
 
, and GAPDH have been previously de-
scribed (18). Other primers and probes included IL-12 (34),
granzyme B (35), and inducible nitric oxide synthase (iNOS; ref-
erence 36). GAPDH was used as a positive control gene for intact
RNA and efficiency of RT.
 
Data Analysis.
 
Urine protein estimations, serum anti-Fx1A
Ab levels, leukocyte counts, popliteal LN weight, and lympho-
cyte FACS
 
Ò
 
 analysis for each group were expressed as mean 
 
6
 
SEM. Comparisons between groups were made by analysis of
variance (ANOVA), and when significant were examined by
Bonferroni-Dunn multiple comparisons post hoc test. Semiquan-
titative RT-PCR results were treated as parametric data with
comparisons between groups made by ANOVA and a Bonfer-
roni-Dunn post hoc test, and expressed graphically as the median
PCR cycle number at which PCR product was first identified. 
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This is intentionally conservative analysis of PCR data, as differ-
ences in product expression are exponential.
 
 P 
 
# 
 
0.05 was con-
sidered significant, unless reduced by Bonferroni-Dunn correc-
tions.
 
Results
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Lewis rats were
depleted of CD8
 
1
 
 T cells by combination ATx and anti-
CD8 mAb therapy (MRC OX-8), either before (early
CD8
 
1
 
 T cell depletion group) or 6 wk after (late CD8
 
1
 
 T
cell depletion group) immunization with Fx1A in CFA.
The CD8
 
1
 
 T cell–depleted rats were compared with those
immunized with Fx1A in CFA (normal HN group), ATx
rats immunized with Fx1A in CFA (ATx/HN group), and
rats immunized only with CFA (CFA control group).
Marked depletion of CD8
 
1
 
CD3
 
1
 
 PBLs to 0.5–1.0% of
CD3
 
1
 
 cells was achieved until the completion of the ex-
periment at 12 wk after immunization (Table 1). There
was no difference in CD8
 
1
 
CD3
 
1
 
 PBLs between CFA con-
trol, normal HN, and ATx/HN groups (21.8–25.5% of
CD3
 
1
 
 cells) throughout the course of the experiment. Full
blood counts were not different between groups, with
white cell counts of 8.4 
 
6 
 
2.3 
 
3 
 
10
 
9
 
/liter in normal HN vs.
6.6 
 
6 
 
3.1 
 
3
 
 10
 
9
 
/liter in CD8
 
1
 
 T cell–depleted rats (
 
P
 
 5
 
NS), and total lymphocyte counts of 1.8 
 
6 
 
0.3 
 
3
 
 10
 
9
 
/liter
vs. 1.6 
 
6 
 
0.4 
 
3
 
 10
 
9
 
/liter, respectively (
 
P
 
 5 
 
NS).
In both normal HN and ATx/HN, proteinuria devel-
oped by 8 wk and had increased further at 12 wk. In the
early and late CD8
 
1
 
 T cell–depleted groups, urinary pro-
tein remained within the normal range observed in CFA
controls (Fig. 1 
 
a
 
). There was no evidence of glomerular
barrier dysfunction in CD8
 
1
 
 T cell–depleted groups. Anti-
Fx1A Ab responses were not different between CD8
 
1
 
 T
cell–depleted, normal HN, and ATx/HN groups (Fig. 1 
 
b
 
).
CFA controls did not produce an Ab response. In keeping
with the Fx1A Ab responses, glomerular Ig deposition was
not different between early or late CD8
 
1
 
 T cell–depleted
and normal HN groups, with none detected in CFA con-
trols (Fig. 1 
 
c
 
 and see Fig. 4). Glomerular C3 deposition
was also not different between early CD8
 
1
 
 T cell–depleted
and normal HN groups, and was absent in CFA controls
(Fig. 1 
 
c
 
 and see Fig. 4).
These experiments were repeated on four occasions with
a minimum of five rats in each treatment group and CD8
 
1
 
T cell–depleted rats never developed proteinuria. At 8–10
wk proteinuria was 7.8 
 
6 
 
0.8 mg/100 g body wt/day
(mean 6 SEM) in early CD81 T cell–depleted hosts (n 5
41) compared with 73.5 6 14.2 in HN controls (n 5 18, P ,
0.0001). The protein measurements in urine were not dif-
ferent from those in CFA immunized controls, which was
3.6 6 0.3 mg/100 g body wt/day (n 5 24, P 5 NS). In one
of these experiments, an additional control group was
treated with A6, an mAb that has the same isotype (IgG1)
as MRC OX-8 but no reactivity with rat cells. This mAb
had no effect on development of antibodies in sera or
glomeruli, nor on proteinuria. At 8 wk, A6-treated rats had
55.5 6 24.5 mg/100 g body wt/day (mean 6 SEM) pro-
teinuria vs. normal HN of 63.5 6 29.5 mg/100 g/day.
Ab isotype switching is controlled by cytokines pro-
duced by T cells. To examine if ATx or CD81 T cell de-
pletion affected such switching, anti-Fx1A IgG Ab isotypes
were examined at 4 and 8 wk. Similar levels of IgG1,
IgG2a, and IgG2b were found in early and late CD81 T
cell–depleted, ATx/HN, and normal HN groups (Fig. 2).
In all these groups, at 4 wk only Th2 induced noncomple-
ment-fixing IgG1 was significantly greater than CFA con-
trols. With Th1-induced IgG2a and IgG2b complement-
fixing isotypes, the increase was not significant. By 8 wk,
the IgG1 response had further increased, and a significant
IgG2a but not IgG2b, response had developed. These find-
ings demonstrated that CD81 T cell depletion did not af-
fect IgG isotype switching.
Characterization of Mononuclear Cell Infiltrates in Glomeruli
and Interstitium. At 12 wk a glomerular infiltrate of T cells
(a/b-TCR1, CD41, and CD81) and macrophages, but not
NK cells, was identified in normal HN but not in early
CD81 T cell–depleted and CFA control groups (Figs. 3 a
Table 1. FACSÒ Analysis of PBLs Comparing CD81 T Cell–depleted with CD81 T Cell–replete HN Groups
CD81CD31 cells/CD31cells (%)
Group 0 wk* 6 wk‡ 12 wk n
CFA control 23.15 6 2.20 25.68 6 1.38 24.63 6 0.98 3
Normal HN 25.53 6 2.15 24.43 6 1.91 25.35 6 2.05 3
ATx/HN 24.97 6 0.84 22.14 6 0.76 21.78 6 0.77 5
Early CD8 depletion/HN 0.47 6 0.15§ 0.40 6 0.08§ 1.01 6 0.50§ 5
Late CD8 depletion/HN 22.57 6 0.79 20.17 6 2.07 1.04 6 0.40§ 5
Prolonged CD81 cell depletion was achieved with ATx followed by anti-CD8 mAb therapy (MRC OX-8). Values represent mean 6 SEM, per-
centage total CD31 cells (G4.181) that are CD81CD31 (MRC OX-81G4.181).
*Time of immunization.
‡Before CD81 T cell depletion in group 5.
§P , 0.0001 for comparisons with all CD81 T cell replete groups. ANOVA followed by Bonferroni-Dunn post hoc multiple comparisons test.1778 CD81 T Cell Depletion Prevents Heymann Nephritis
and 4). These findings show that depletion of CD81 T cells
prevented the accumulation of all mononuclear cell subsets
into glomeruli, not just of the CD81 T cell subset. The
number of CD81 T cells and NK cells in glomeruli from
the CD81 T cell–depleted group was similar to that in
CFA controls that do not develop disease. These CD81 T
cells were probably CD81CD32 NK cells present in pe-
ripheral blood and lymphoid tissue (data not shown).
MRC OX-8 mAb therapy initially depletes both CD81 T
cells and NK cells, but NK cells rapidly regenerate periph-
erally, unlike CD81 T cells which require the thymus.
The renal cortical infiltrate identified at 12 wk in normal
HN, comprising both T cells (a/b-TCR1, CD41, and
CD81) and macrophages, but not NK cells, was absent in
early and late CD81 T cell–depleted, and CFA control
groups (Fig. 3 b). There was a small but significant increase
in a/b-TCR1 cells and macrophages in the late CD81 T
cell–depleted group compared with CFA controls; how-
ever, the increase in a/b-TCR1 cells was not reflected by
an increase in CD41 or CD81 T cells. Only small numbers
of CD81 T cells, less than in CFA controls, were detected
in the CD81 T cell–depleted groups.
Analysis of Mononuclear Cell Cytokine mRNA in Glomeruli.
The functional potential of the cellular infiltrate in glomer-
uli, associated with proteinuria in normal HN, was charac-
terized by RT-PCR of mRNA for cytokines (Fig. 5).
mRNA for cytokines and effector molecules of Th1 cells
(IFN-g, lymphotoxin, and IL-2), cytotoxic cells (granzyme
A and perforin, but not granzyme B), and macrophages
(TNF-a, IL-10, IL-12, and iNOS) was increased in normal
HN compared with the CD81 T cell–depleted HN groups
and CFA controls. Both early and late CD81 T cell–depleted
groups had cytokine and effector molecule mRNA levels at
or below that observed in CFA controls. This is not sur-
prising as mononuclear cells were not identified within the
glomeruli of these groups. There was no difference between
groups in the expression of the Th2 cell cytokine IL-4.
Other Th2 cytokines such as IL-5 and IL-6 were not stud-
ied as their mRNA is not readily detected in isolated glom-
eruli from normal HN or CFA control rats (18). The persis-
Figure 1. CD81 T cell depletion in HN prevented proteinuria in the presence of elevated serum anti-Fx1A Ab levels and glomerular IgG deposition.
(a) Proteinuria in early or late CD8-depleted HN was not significantly greater than that in CFA controls. In normal HN and ATx/HN, proteinuria was
detected from 8 wk, and was not different between these groups at 8 and 12 wk. Proteinuria was significantly greater in normal HN and ATx/HN than
in early or late CD8-depleted HN, or CFA controls, at 8 (P , 0.0036) and 12 wk (P , 0.0002), for all comparisons. Values represent the mean 6 SEM
(n 5 5) of urine protein excretion, expressed as mg/100 g body wt/day, measured by colorimetric assay. (b) Serum anti-Fx1A Ab responses were not dif-
ferent between HN, ATx/HN, or early and late CD8-depleted HN at all times. CFA controls did not develop an anti-Fx1A Ab response, with P ,
0.0006 for comparisons at all times with the other groups. Values represent the mean 6 SEM (n 5 5) of total anti-Fx1A Ab levels, expressed as per-
centage binding of known strongly positive serum (Fx1A Ab titer 1:250), measured by ELISA. (c) Glomerular Ig and C3 deposition at 12 wk were not
significantly different between normal HN and early or late CD8-depleted HN groups (C3 staining for late CD8-depleted HN not tested). Values repre-
sent the mean 6 SEM (n 5 5) of glomerular IgG (MRC OX-12) or C3 deposition on IP staining, scored from 0 (absent) to 3 (intense). Statistical analysis
by ANOVA followed by Bonferroni-Dunn post hoc multiple comparisons test.
Figure 2. Serum anti-Fx1A
Ab IgG isotype switching and
subclass production in HN were
not altered by CD81 T cell de-
pletion. IgG subclasses were de-
tected in similar proportions at 4
and 8 wk in CD8-depleted HN,
ATx/HN, and normal HN
groups. CFA controls did not
mount an Fx1A Ab response. At
4 wk, only the Th2-mediated
IgG1 response was significantly
raised above controls. By 8 wk the IgG1 response had increased further, and a significant Th1 mediated IgG2a response was identified compared with
CFA controls. There was no significant-IgG2b response. Values represent mean 6 SEM (n 5 5) of anti-Fx1A Ab levels, expressed as percentage binding
of known strongly positive serum (Fx1A Ab titer 1:250), measured by ELISA. *P , 0.005 for comparisons between CFA controls and all other groups.
ANOVA followed by Bonferroni-Dunn post hoc multiple comparisons test.1779 Penny et al.
tent detection of background perforin mRNA despite CD81
T cell depletion is most likely due to CD41 cytotoxic T
cells or constitutive expression by NK cells (37, 38).
Lymph Node Responses. To examine whether CD81 T
cell depletion influenced early responses in popliteal LN
draining the primary sites of immunization, LN from an
early CD81 T cell–depleted group were compared with
those from normal HN (CFA/Fx1A), CFA control, and
normal unimmunized groups at 2 wk.
The weight of LNs from the CD81 T cell–depleted
group was not significantly different from normal HN or
CFA controls, and all weighed significantly more than LNs
from unimmunized rats (Fig. 6 a). CD81 T cell depletion
was confirmed in the CD81 T cell–depleted group, with
appropriate reciprocal changes in the proportion of other
lymphocyte subsets (Fig. 6 b). LNs from CFA controls and
normal HN, when compared with unimmunized normals,
had a decrease in the proportion of B cells and an increase
in the proportion of T cells, especially CD81 T cells.
CD81 T cell depletion did not impair cytokine and ef-
fector molecule mRNA expression in LN draining sites of
immunization. Cytokine mRNA for Th1, Th2, and cyto-
toxic cells was increased in LNs from normal HN and
CD81 T cell–depleted HN when compared with unim-
munized normals (Fig. 7). The presence in LNs of mRNA
for the cytotoxic cell molecules granzyme A, granzyme B,
and perforin, despite the confirmed depletion of CD81 T
cells, suggests these molecules were from NK or cytotoxic
CD41 T cells (37–40).
Discussion
This study implicates CD81 cytotoxic T cells as media-
tors of glomerular injury in active HN, a disease thought to
be principally mediated by the MAC of complement (6,
41). Persistent depletion of CD81 T cells by ATx and anti-
CD8 mAb therapy, both early and late in the course of dis-
ease, prevented the development of proteinuria. Depletion
of CD81 T cells did not affect the Ab response, which is
not unexpected, as CD41 T cells provide help for anti-
Fx1A Ab responses in HN (42). Glomerular deposition of
IgG and C3 was also not different between CD81 T cell–
depleted and normal HN groups. CD81 T cell–depleted
rats also did not develop the glomerular infiltrate of acti-
vated mononuclear cells, including CD81 cytotoxic effec-
tor cells and macrophages, seen in HN. ATx alone, which
did not result in CD81 T cell depletion, did not alter the
natural history of HN. The finding that an isotype-
matched control mAb that does not react with rat T cells
had no effect on development of disease suggests that the
effect of the anti-CD8 mAb is specific and not due to a
nonspecific inhibitory or inflammatory reaction. Nonspe-
cific effects from endotoxin are also unlikely, as contamina-
tion was minimal, there was no leucocytosis in this group,
and the cytokine profiles in the popliteal node at the site of
immunization were not enhanced in mAb treated hosts.
Furthermore, with the early treatment with mAb it would
have been eliminated before immunization. In previous
studies we have shown that anti-CD8 mAb therapy alone,
which led to only temporary depletion of CD81 T cells,
delayed the onset of proteinuria (17). These results, espe-
cially of the effect of late CD81 T cell depletion, indicated
CD81 T cells were required in the final effector phase that
leads to proteinuria.
Prevention of HN with CD81 T cell depletion was not
due to the modification of initial immune events in LN
draining sites of immunization or the isotype of anti-Fx1A
Ab. CD81 T cell–depleted rats had a similar increase in LN
size, as well as Th1 and Th2 cell cytokine activation, com-
pared with that in normal HN rats. In both CD81 T cell–
depleted and normal HN, IgG1 was produced first, then
IgG2a and a lesser IgG2b response, which accords with
previous reports in HN (43). Thus ATx and anti-CD8
mAb therapy did not alter the Th1/Th2 response. Further
evidence against an alteration of initial immunization
events is that late depletion of CD81 T cells, well after the
initiation of serum Ab responses and glomerular Ig deposi-
tion, prevented disease. Thus, in the presence of a normal
serum Ab response to Fx1A and deposition of IgG in
Figure 3. The mononuclear cell infiltrate seen in the glomeruli and re-
nal cortex in normal HN at 12 wk was prevented by early CD81 T cell
depletion and significantly attenuated by late CD81 T cell depletion. (a)
A glomerular infiltrate of a/b-TCR1 (R73), CD41 (W3/25), and CD81
(MRC OX-8) cells, and macrophages (ED-1), but not NK cells (3.2.3),
was present in normal HN at 12 wk. This infiltrate was not present in
early or late CD8-depleted HN. Values represent the mean 6 SEM (n 5
5) of cells per glomerulus (10 glomeruli per rat). (b) A renal cortical infil-
trate of a/b-TCR1, CD41, and CD81 cells, and macrophages, but not
NK cells, was present in untreated HN at 12 wk. This infiltrate was ab-
sent in early CD8-depleted HN. In late CD8-depleted HN there was a
small infiltrate staining only for R73 and ED-1. Values represent the
mean  6  SEM (n 5 5) of cells per HPF (10 HPF per rat). *P , 0.01, **P ,
0.001, ***P , 0.0001. ANOVA followed by Bonferroni-Dunn post hoc
multiple comparisons test.1780 CD81 T Cell Depletion Prevents Heymann Nephritis
Figure 4. CD81 T cell deple-
tion in HN did not prevent
glomerular deposition of IgG or
C3, but abrogated the infiltration
of mononuclear cells including
CD81 cells. (a–c) Glomerular
IgG and C3 deposition were not
different between normal HN
and CD8-depleted HN groups.
Note the amorphous staining of
IgG and C3 within tubular lu-
mina in the proteinuric normal
HN rat. (d) The glomerular infil-
trate of CD81 cells in normal
HN was absent in CD8-depleted
HN hosts.
Figure 5. At 12 wk, CD81 T cell deple-
tion prevented the increase in Th1, cyto-
toxic T cell, and macrophage cytokine ex-
pression in glomeruli from rats with HN.
Significant increases in cytokine mRNA ex-
pression for Th1 cells, cytotoxic cells, and
macrophages were seen in normal HN com-
pared with the background expression in
CFA controls. These increases were not de-
tected in early and late CD8-depleted glom-
eruli. Cytotoxic cell molecules in rats
depleted of CD81 T cells were probably
from NK cells. Results expressed as the me-
dian cycle number (n 5 4) at which PCR
product was first detected, measured at five-cycle intervals. *P , 0.01, **P , 0.001, ***P , 0.0001. U, PCR product undetectable. ANOVA followed by
Bonferroni-Dunn post hoc multiple comparisons test.1781 Penny et al.
glomeruli, proteinuria does not develop in CD81 T cell–
depleted rats.
HN has been considered the archetypal model for Ab-
mediated injury via complement activation, with MAC
causing damage to glomerular epithelial cells (GEC). In this
study, CD81 T cell–depleted hosts had normal IgG and C3
deposition. This indicates the Ig had bound to GEC and
activated complement, but this alone did not result in in-
jury leading to proteinuria. A direct pathogenic role for
MAC in active HN was discounted by Leenaerts et al. (9),
who demonstrated the development of HN in PVG rats
deficient in C6, which are unable to assemble MAC. This
study related increasing size of the subepithelial immune
deposits to glomerular barrier dysfunction. However, other
studies report no correlation between serum Ab titer or the
size of immune deposits and proteinuria (44, 45). Our stud-
ies suggest alternative non-Ab-mediated effector mecha-
nisms should be considered.
A possible explanation for the pathogenesis of HN is that
after immunization with Fx1A the antigen is presented by
host class II MHC that activates Th1 and Th2 CD41 T
cells that provide help for B cells in draining LN to pro-
duce an Ab response (30, 42). These Ab bind to antigen on
GEC and form subepithelial immune deposits. The re-
sponse of GEC to this causes antigen presentation by class I
MHC on these cells to CD81 T cells. This response may
also require help from class II–restricted CD41 T cells (17).
Alternatively, there may be direct presentation of exoge-
nous antigen to MHC class I–restricted CD81 T cells as
this pathway of antigen presentation has recently been de-
scribed (46). As GEC are capable of expressing MHC class
I and II and costimulatory molecules (47–49) they may
themselves act as antigen-presenting cells. The activation of
CD81 T cells appears to be much slower than the activa-
tion of the CD41 T cell–dependent B cell response to
Fx1A.
The final effector mechanism, resulting in GEC injury
and proteinuria, is most likely direct CD81 T cell–medi-
ated cytotoxicity via the granule exocytosis perforin path-
way. This is supported by increased mRNA for granule
exocytosis pathway molecules in CD81 T cell–depleted
glomeruli compared with HN. Glomerular injury may be
compounded by the cytotoxic products of glomerular mac-
rophages (16, 18, 50), whose recruitment into glomeruli is
dependent upon activated CD41 and CD81 T cells (51).
Criteria for determining the functional significance of
cell-mediated immunity in GN (1) have now been fulfilled
for HN. First, an infiltrate comprising the elements of ef-
fector cell–mediated immunity, including Th1 and cyto-
toxic T lymphocytes, and macrophages, has been detected
within glomeruli. Second, the influx of effector cells is
temporally related to the development of proteinuria.
Third, functional activation of the potential effector cells,
Figure 6. At 2 wk, CD81 T cell depletion did not prevent an increase
in the weight of immunized popliteal LNs. (a) There was a significant in-
crease in the weight of all immunized (CFA control, normal HN, early
CD8-depleted HN) compared with unimmunized LNs, with LNs from
normal HN group being the heaviest. LNs from the early CD81 T cell–
depleted group did not differ significantly from CFA controls or normal
HN. Values represent the mean 6 SEM (n 5 4) of popliteal LN weight in
grams. (b) There was a significant decrease in the proportion of B cells
(OX-331), and an increase in CD31 T cells (G4.181), which included
both CD41CD31 (OX-351G4.181) and CD81CD31 (OX-81G4.181)
cells. There were virtually no CD81CD31 (OX-81G4.181) cells present
in the early CD81 T cell–depleted group. Appropriate reciprocal changes
to CD81 T cell–depleted LNs were seen in LNs from the other groups.
Values represent the mean 6 SEM (n 5 4) of labeled lymphocytes as per-
centage of total gated population identified by FACSÒ analysis. *P , 0.01,
**P , 0.001, ***P , 0.0001. ANOVA followed by Bonferroni-Dunn
post hoc multiple comparisons test.
Figure 7. At 2 wk, CD81 T cell deple-
tion did not alter the balance of Th1 and
Th2 cytokine expression in LNs from rats
with HN. Immunization with CFA and
CFA/Fx1A resulted in significantly in-
creased expression of Th1, Th2, and cyto-
toxic cell cytokines when compared with
unimmunized LNs. This was not signifi-
cantly decreased by CD81 T cell depletion.
Cytotoxic cell molecules in rats depleted of
CD81 T cells were probably from NK cells.
Results are expressed as the median cycle
number (n 5 4) at which PCR product was
first detected, measured at five-cycle inter-
vals. *P , 0.01, **P , 0.001. U, PCR prod-
uct undetectable. ANOVA followed by
Bonferroni-Dunn post hoc multiple com-
parisons test.1782 CD81 T Cell Depletion Prevents Heymann Nephritis
CD81 T cells and macrophages, has been demonstrated by
the detection of the mRNA for their cytokines (TNF-a,
TNF-b, IFN-g, etc.), cytolytic molecules (perforin, gran-
zymes), and other mediators, such as iNOS, reactive oxygen
species (16). Production of these molecules could directly or
indirectly cause tissue injury. Fourth, lymphocytes have been
specifically sensitized to relevant glomerular antigens (10),
and transfer of sensitized lymphoid cells induces GEC injury
in vitro (11) and in vivo (13, 52). Fifth, depletion of CD81
T effector cells abrogates injury. We have attempted recon-
stitution of CD81 T cell–depleted rats immunized for HN
with sensitized CD81 T cells, but these cells have been short
lived and did not reconstitute the CD81 T cell population
(Penny, M.J., unpublished observation).
Our study suggests that glomerular injury in HN is me-
diated by cytotoxic CD81 effector T cells. This is an un-
usual effector mechanism for autoimmunity, and is best
described in experimental immune-mediated diabetes mel-
litus (53, 54). CD81 lymphocytes are thought to have a
role as effector cells in nephrotoxic serum nephritis (55). In
the majority of autoimmune models, especially those in-
duced by immunization with CFA, and including those of
nephritis (1, 2), injury is mediated by CD41 T cells and
macrophages. This work may be of relevance to the patho-
genesis of human membranous nephropathy and other
forms of GN, and may result in specific therapies that im-
prove treatment.
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